Infliximab biosimilar CT-P13 is interchangeable with its originator for patients with inflammatory bowel disease in real world practice

Infliximab biosimilar CT-P13 is interchangeable with its originator for patients with inflammatory bowel disease in real world practice

Background/Aims An interim analysis of post-marketing surveillance of CT-P13, an infliximab biosimilar, was performed to evaluate its safety and efficacy in Japanese patients with inflammatory bowel disease. Methods Patients were prospectively enrolled between November 2014 and March 2017, after the...

Full description

Bibliographic Details
Main Authors: Tomoo Nakagawa, Taku Kobayashi, Kiyohiro Nishikawa, Fumika Yamada, Satoshi Asai, Yukinori Sameshima, Yasuo Suzuki, Mamoru Watanabe, Toshifumi Hibi
Format: Article
Language:English
Published: Korean Association for the Study of Intestinal Diseases 2019-10-01
Series:Intestinal Research
Subjects:
infliximab
biosimilar
ct-p13
post-marketing surveillance
inflammatory bowel disease
Online Access:http://www.irjournal.org/upload/pdf/ir-2019-00030.pdf

Internet

http://www.irjournal.org/upload/pdf/ir-2019-00030.pdf

Similar Items